Monte Rosa Therapeutics unveils preclinical data on targeting undruggable CCNE1 in solid tumors

Monte Rosa Therapeutics unveils preclinical data on targeting undruggable CCNE1 in solid tumors
Monte Rosa targets CCNE1 tumors

Monte Rosa Therapeutics has presented preclinical data at AACR26 regarding its CCNE1-directed molecular glue degrader, aimed at treating CCNE1-amplified solid tumors.

The approach suggests a new potential pathway for targeting a historically undruggable cancer gene, which could open future research and therapeutic avenues. Full details were shared as part of the company’s scientific presentation at the event.

Monte Rosa Therapeutics has previously championed early engagement and expanded opportunities for scientists during Women’s History Month. CEO Markus Warmuth is set to join industry experts at AACR2026 to discuss proximity-induced therapies. The company continues to highlight its research focus at major scientific forums.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.